UNSPSC 51283929: Sulfathiazole

This classification denotes a sulfonamide anti-infective agent with the molecular formula C9H9N3O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y7FKS2XWQH, chemically known as 4-amino-n-1,3-thiazol-2-ylbenzenesulfonamide but generally known as sulfathiazole, which bears US NIH Compound Identifier 5340. European Medicines Agency schedules Sulfathiazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10731MIG.

UNSPSC 51283929 Sulfathiazole is a Commodity code that represents a narrow pharmaceutical ingredient category, but recent state and local solicitations tagged with this code show no direct procurement of sulfathiazole itself. Instead, the opportunities involve broader pharmaceutical and medical supply acquisitions: Seminole County, Florida is procuring naloxone and drug deactivation systems; the City of Tampa is sourcing medical and first aid supplies for the Fire Department; the Texas Health and Human Services Commission is exploring direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is establishing contracts for generic multi-source pharmaceuticals and over-the-counter products. The issuing bodies span county health departments, municipal fire and rescue divisions, state pharmacy programs, and multi-state cooperative purchasing organizations. None of these solicitations target sulfathiazole specifically, suggesting the code has little active procurement demand in recent state and local markets and may be misapplied or dormant under this taxonomy.

Recent activity concentrates in Florida, Minnesota, Texas, and multi-state purchasing vehicles. Seminole County's IFB for naloxone and drug deactivation systems (posted June 30, 2026, due July 26, 2023) sought 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries. The City of Tampa issued IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies totaling an estimated $700,000, designated as a sheltered market opportunity for certified Small Local Business Enterprises. The Minnesota Multistate Cooperative Purchasing Alliance posted RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish generic pharmaceutical and OTC contracts across state and local facilities in Minnesota and Oregon. The Texas HHS Commission issued RFI HHS0017013 (posted April 3, 2026) to explore vendor capabilities for direct-to-manufacturer prescription programs. The code's weak alignment with actual procured goods suggests that business development professionals should verify coding accuracy before pursuing opportunities nominally classified under sulfathiazole.